Banca de DEFESA: ANDRESSA LETICIA LOPES DA SILVA

Uma banca de DEFESA de DOUTORADO foi cadastrada pelo programa.
STUDENT : ANDRESSA LETICIA LOPES DA SILVA
DATE: 22/06/2022
TIME: 08:30
LOCAL: Espaço virtual
TITLE:

EVALUATION OF ANTITUMOR ACTIVITY OF GUANYLIDRAZONE DERIVATIVES IN HUMAN GLIOBLASTOMA LINEAGE (GBM02)

KEY WORDS:

Human Glioblastoma, Guanylhydrazones, Synthetic derivative, Antitumor.

PAGES: 75
BIG AREA: Outra
AREA: Multidisciplinar
SUMMARY:

 

Cancer is considered a public health problem and can be associated with the four main causes of death in the world. The number of new cases grows progressively, highlighting the need for treatments with low cost and high curative rate. Among the types of cancer that are most aggressive are gliomas. Gliomas are considered one of the main types of central nervous system tumors. They originate from glial cells and are the most common glioblastoma in adults. Due to its high molecular heterogeneity and a large number of genetic mutations, the development of specific target prototypes is necessary. Guanylhydrazones belong to the class of hydrazones, which are characterized by the presence of the imine group linked to an amine and are considered more stable, presenting several activities in the literature, such as antitumor activity against leukemia, melanoma, lung, kidney and colon cancer. New researches using guanylhydrazones against human glioblastoma are being developed, since the number of researches focused on this lineage is still not expressive. The present work aims to evaluate the in vitro antitumor activity of guanylhydrazone derivatives in human glioblastoma cells. To assess the antitumor effect of guanylhydrazones, the MTT test was performed with GBM02 cells, where the positive control was Temozolamide (TMZ). Cells were treated with different concentrations of derivatives for 48 hours. For the study on morphology, the GBM02 cells were plated and adhered to cover slips, with TMZ as a positive control and DMSO 0.1% as a negative control. As a result of the in vitro antitumor activity against GBM02, the derivatives that showed the best IC50 were LQM 240 with 3.54 µM followed by LQM 243 with 4.15 µM. Regarding the inhibitory effect, all compounds in the series had a cytotoxic effect greater than 70%, except for LQM 242 which had an effect of 42.92% in 48 hours. Regarding morphology, LQM 14 and LQM 243 derivatives morphologically affected GBM02 cells, both by loss of cytoplasmic content, cell membrane disruption and content leakage. Regarding the cytotoxicity assay, none of the compounds used in the test showed toxicity and all demonstrated to be selective for human glioblastoma cells. In view of the results, other studies such as: antitumor of guanylhydrazones 72 hours, morphology of other derivatives, cytotoxic effect on monocytes and lymphocytes, evaluation of selectivity and antimigratory effect and tests in the Muse flow minicytometer, are being carried out.

BANKING MEMBERS:
Presidente - 1369387 - JOAO XAVIER DE ARAUJO JUNIOR
Interno - 1653558 - LUCIANO APARECIDO MEIRELES GRILLO
Interna - 1358530 - MAGNA SUZANA ALEXANDRE MOREIRA
Externa ao Programa - 2272670 - ALINE CAVALCANTI DE QUEIROZ
Externa à Instituição - ELITA SCIO FONTES - UFJF
Externa à Instituição - MARIANA DA SILVA SANTOS - CESMAC